Trustworthy AI tools for personalized oncology

The project aims to develop trustworthy AI tools for personalized oncology to enhance diagnosis, outcome prediction, and treatment recommendations, ensuring reliability and transparency in clinical practice.

Subsidie
€ 1.999.225
2023

Projectdetails

Introduction

Modern machine learning algorithms have the potential to accelerate personalized medicine at a fast pace. To date, first tasks in medicine are being addressed with machine learning algorithms that surpass humans in terms of accuracy and speed, including diagnosis, outcome prediction, and treatment recommendation.

Trust in AI Models

However, for widespread adoption in clinical practice, good performance in terms of speed and accuracy is not sufficient: practitioners also need to be able to trust a model’s prediction in all stages of its life cycle.

Development of Trustworthy AI Tools

I will facilitate an efficient interaction of clinicians with AI models by developing trustworthy AI tools for personalized oncology:

  1. I will develop trustworthy AI tools and algorithms for diagnosis and stratification of cancer patients.
  2. I will establish a framework for reliable and transparent modeling of personalized outcomes and therapy decisions in oncology.

Project Outcomes

TAIPO will result in novel algorithms and software tools for quantifying and improving the trustworthiness of AI models that I will apply to three clinical applications:

  1. Trustworthy AI-based skin lesion classification based on dermoscopic images.
  2. Stratification and personalized outcome modeling for patients with acute myeloid leukaemia (AML) based on omics data.
  3. Therapy recommendation for metastatic breast cancer patients based on electronic health records.

Impact on Clinical Practice

TAIPO will increase the throughput of trustworthy diagnoses of skin lesions and pave the way for low-cost access to diagnostic care. It will empower clinicians to make personalized and reliable therapy decisions, which we will demonstrate at the example of AML and metastatic breast cancer.

Contribution to the Field

Our novel algorithms to evaluate and improve the reliability of AI models are a crucial contribution to close the gap between in-silico AI-bench and bedside and will further push the field of trustworthy machine learning with many applications of AI in medicine.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.999.225
Totale projectbegroting€ 1.999.225

Tijdlijn

Startdatum1-5-2023
Einddatum30-4-2028
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERGpenvoerder

Land(en)

Germany

Vergelijkbare projecten binnen European Research Council

ERC Proof of...

AI-based leukemia detection in routine diagnostic blood smear data

Develop LeukoScreen, an AI software to enhance the speed and accuracy of acute promyelocytic leukemia diagnosis, improving patient outcomes and optimizing laboratory workflows.

€ 150.000
ERC Consolid...

Foundation models for molecular diagnostics - machine learning with biological ‘common sense’

FoundationDX aims to enhance molecular diagnostics by using self-supervised learning on diverse biomolecular data to accurately predict cancer subtypes and treatment outcomes without extensive labeled datasets.

€ 2.000.000
ERC Starting...

Interpretable Artificial Intelligence across Scales for Next-Generation Cancer Prognostics

This project aims to enhance cancer prognosis and treatment selection by applying advanced machine learning to whole-slide images, addressing key knowledge gaps and improving model explainability.

€ 1.494.810
ERC Starting...

Transformative Pediatric Brain Cancer Imaging using Integrated Biophysics-AI Molecular MRI

Develop a novel AI-driven molecular MRI technology for rapid, noninvasive monitoring of pediatric brain cancer treatment response, enhancing precision medicine and understanding of tumor dynamics.

€ 1.497.669
ERC Consolid...

The first AI-guided toxicity atlas for safer and more effective abdominal radiation therapy

The AIDose project aims to create a 3D toxicity risk atlas for thoracic and abdominal organs using AI to enhance radiotherapy planning and reduce treatment-related toxicities in cancer patients.

€ 1.999.972

Vergelijkbare projecten uit andere regelingen

EIC Accelerator

IOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology.

The project aims to enhance cancer immunotherapy efficacy by developing a validated biomarker assay to predict patient responses, potentially doubling survival rates for lethal tumors.

€ 2.496.112
Mkb-innovati...

Onderzoek naar AI-based second opinion

Het project onderzoekt de haalbaarheid van een AI-platform voor optimale kankerbehandelplannen via geüploade patiëntdata.

€ 20.000
Mkb-innovati...

Geautomatiseerde ondersteuning voor gepersonaliseerde revalidatie in de oncologie

Pinktrainer ontwikkelt een applicatie voor oncologische fysiotherapie en voedingsadvies, gericht op gepersonaliseerde interventies en het verbeteren van patiëntresultaten door data-analyse en samenwerking met het Evidencio platform.

€ 125.601
Mkb-innovati...

AI-based medical assistant - Herkennen en classificeren van tumoren m.b.v. kunstmatige intelligentie

Dit project ontwikkelt een geavanceerde beeldherkenningstechnologie voor realtime screening van eiwittypologieën in biopten, om de behandeling van complexe tumoren te verbeteren.

€ 200.000
EIC Accelerator

The first IVDR-approved commercial software solutions for AI-powered RNA-based companion and precision cancer diagnostics of acute myeloid leukaemia and bladder cancer

Qlucore aims to revolutionize precision oncology by developing AI-driven diagnostic software for cancer, enhancing accuracy in gene analysis and improving survival rates across Europe.

€ 2.491.650